Vesicle membrane fusion induced by the concerted activities of sphingomyelinase and phospholipase C.
When vesicles composed of an equimolar mixture of sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, and cholesterol are treated with phospholipase C, phospholipid hydrolysis occurs without major changes in vesicle architecture. In the same way, addition of sphingomyelinase leads only to sphingomyelin cleavage. However, when both enzymes are added together, their joint hydrolytic activities give rise to leakage-free vesicle aggregation, lipid mixing, and aqueous contents mixing, i.e. vesicle fusion. The contribution of both enzymes is unequal, the main role of sphingomyelinase being the production of relatively large amounts of ceramide that will facilitate the lamellar-to-nonlamellar transition in the formation of the fusion pore, whereas phospholipase C provides mainly a localized, asymmetric, high concentration of diacylglycerol that constitutes the trigger for the fusion process. The lipidic end-products of both enzymes cooperate in destabilizing and fusing the membranes in a way that is never achieved through the action of any of the enzymes individually, nor by the products themselves when premixed with the other lipids during liposome preparation. Thus the enzymes appear to be coupled through their reaction products. This is the first observation of membrane fusion induced by the concerted activities of two enzymes. Besides, considering that both diacylglycerol and ceramide are important metabolites involved in cell signaling, it may also provide new ideas in the exploration of "cross-talk" phenomena between different signal transduction pathways.
Ruiz-Argüello
M B
MB
Grupo Biomembranas (Unidad Asociada al C.S.I.C.), Departamento de Bioquímica, Universidad del País Vasco, Aptdo. 644, 48080 Bilbao, Spain.
Goñi
F M
FM
Alonso
A
A
D002518:Ceramides; D004075:Diglycerides; D008081:Liposomes; D008561:Membrane Fusion; D010539:Permeability; D010618:Phenanthrolines / Q000494:pharmacology; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; D013108:Sphingomyelin Phosphodiesterase / Q000494:pharmacology*; D013109:Sphingomyelins; D010738:Type C Phospholipases / Q000037:antagonists & inhibitors / Q000494:pharmacology*
D002518:Ceramides; D004075:Diglycerides; D008081:Liposomes; D010618:Phenanthrolines; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; D013109:Sphingomyelins; C001635:ferroin; D010738:Type C Phospholipases; D013108:Sphingomyelin Phosphodiesterase